Drug Trial Radar · NCT02294630
Aerosolized Surfactant in Neonatal RDS
Last checked: Nov 19, 2026Latest source record: Aug 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
159
Actual
Start
Dec 2014
Primary completion
Jul 2019
Study completion Jul 2020
Sponsor
- Lead sponsor
- Sood, Beena G., MD, MSIndividual
- Sponsor type
- Individual
- First posted
- Nov 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 24 hours
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Respiratory distress syndrome (RDS), caused by surfactant deficiency, is the leading cause of mortality and morbidity in preterm infants. Intratracheal instillation, the only approved means of surfactant delivery, requires endotracheal intubation and mechanical ventilation with their attendant risks. Interventions that decrease need for intubation and mechanical ventilation like noninvasive ventilation (NIV) including nasal continuous positive airway pressure, high flow nasal cannula or nasal intermittent mandatory ventilation are increasingly being used for initial respiratory support in preterm neonates with RDS to improve outcomes. Aerosolized surfactant delivered during NIV is an innovative and promising concept for the treatment of RDS - retaining the advantages of early surfactant with alveolar recruitment while obviating the risks of intubation and mechanical ventilation. The investigators overall hypothesis is that treatment of RDS with aerosolized surfactant in preterm infants undergoing NIV is safe and feasible and will result in short-term improvement in oxygenation and ventilation. The objective of this proposal is to perform a single-center unblinded Phase II randomized clinical trial of aerosolized surfactant for the treatment of RDS in preterm neonates undergoing NIV. Funding Source - FDA-OOPD.
Conditions
- Respiratory Distress Syndrome, Newborn
Interventions
SurfactantDrug
Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events as a Measure of Safety and FeasibilityTime frame: During and within 6 hours after end of study drug administration, expected maximum of approximately 14 hours
- Patient Status as Evaluated by Dose LevelTime frame: During study drug administration, expected maximum of approximately 8 hours for adverse effects and infant comfort; need for intubation was assessed within 72 hours of study intervention.
- Short Term Efficacy as Assessed by Need for IntubationTime frame: Within 72 hours of study intervention
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hutzel Women's Hospital
Detroit, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.